Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
jueves, octubre 29
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
GSK PLC
GSK
NYSE
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$48.14
-0.60
-1.23%
Últ. Act.: Oct 29, 9:30 AM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Dividendos
Comparar
Informe de acciones
PRO
¿Por qué se mueve?:
GSK shares are trading lower after the company reported Q3 financial result...
Ganancias:
Los beneficios de Q3 2026 se publicaron el mié oct 28th, antes de la apertura del mercado
Conferencia telefónica:
La conferencia telefónica más reciente comenzó a las 8:00 a. m., hace 1 día
Haz clic para ver el webcast
GSK Financials
GSK (GSK) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
GSK’s Specialty Drugs Grow by Double Digits While Vaccines Slip in a Q3 Beat
GSK beat Q3 analyst consensus with $1.47 adjusted EPS and $11.95 billion revenue, as specialty drugs offset vaccine drops. 2026 outlook reaffirmed.
Vandana Singh
PRO
UPDATE: GSK Q3 Adj. EPS $1.47 Beats $1.40 Estimate, Sales $11.948B Beat $11.800B Estimate
GSK (NYSE:GSK) reported quarterly earnings of $1.47 per share which beat the analyst consensus estimate of $1.40 by 5 percent. This is a 0.68 percent decrease over earnings of $1.48 per share from the same period last
Benzinga Newsdesk
PRO
GSK FY2031 Revenue expected to be more than $53.204B vs $45.150B Est
GSK (NYSE:GSK) FY2031 Revenue expected to be more than $53.204B vs $45.150B Est
Benzinga Newsdesk
PRO
GSK Affirms FY2026 Adj EPS Guidance of $4.90-$5.00 vs $4.78 Est; Affirms FY2026 Sales Guidance of $44.754B vs $45.150B Est
GSK (NYSE:GSK) affirms FY2026 Adj EPS guidance from $4.90-$5.00 to $4.90-$5.00 vs $4.78 analyst estimate. Affirms FY2026 sales outlook from $44.754 billion to $44.754 billion vs $45.150 billion estimate.
Benzinga Newsdesk
Microsoft, Alphabet On Deck Wednesday As AI Spending, Cloud Growth Face Test
Microsoft and Alphabet headline Wednesday’s reports, with investors weighing whether AI infrastructure spending is translating into durable cloud and advertising growth. GE Vernova, Amphenol, Banco Santander, UBS Group
Benzinga Insights
GSK Races To Protect Profits Before Its HIV Blockbuster Faces Generic Rivals
GSK beats Q2 revenue and earnings estimates, launches a $2.52B cost-savings program, and updates its 2026 guidance.
Vandana Singh
